Please assess the completion status of the following clinical trial:

Trial Title: Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Rheumatoid Arthritis~* At least 3 months prior treatment with Methotrexate (MTX)~* At least 10 swollen joints and 12 tender joints and C-Reactive Protein of at least 1 mg/dl~* Washout required for other disease modifying anti-rheumatic drugs (DMARDS)~Exclusion Criteria:~* participants who have failed more than 3 DMARDs~* participants previously treated with an approved biologic drug~* History of cancer in the last 5 years~* Severe or recurrent bacterial infection~* Any previous or current medical conditions that are contraindications to the use of TNF blocking agents~* Women of Child Bearing Potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Abatacept (ABA) + Methotrexate (MTX) (double-blind [DB]) (Type: ACTIVE_COMPARATOR): Days 1-365
- Infliximab + MTX (DB) (Type: ACTIVE_COMPARATOR): Days 1-365
- Placebo + MTX (DB) (Type: PLACEBO_COMPARATOR): Days 1-197
- Placebo + MTX switched to abatacept + MTX (DB) (Type: EXPERIMENTAL): Participants received placebo plus methotrexate for days 1-197, and abatacept plus methotrexate for days 198-365
- Abatacept (open-label) (Type: EXPERIMENTAL): Days 365 to 729 All participants receive Active Drug

Based on this trial design, predict the completion outcome and termination type (if applicable).